ARTICLE | Clinical News
OxiGene Phase I data
April 5, 2000 7:00 AM UTC
Preliminary results from a U.S. Phase I trial showed that OXGN's Combretastatin A4 Prodrug ( CA4P) was well tolerated at dose levels up to 56 mg/m 2 in 27 evaluable patients who received 5 daily injec...